{ "entity_id": "B-002561", "folder": "Australian-Technical-Advisory-Group-on-Immunisation", "name": "Australian Technical Advisory Group on Immunisation", "type": "Advisory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.health.gov.au/committees-and-groups/atagi", "data_status": "partial", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": true, "has_kpi_targets": true, "has_kpi_results": true, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 7, "n_kpi_targets": 5, "n_kpi_results": 5, "n_outcomes": 10, "verified_own_data": true }, "strategy_profile": { "status": "needs_review", "confidence": "medium", "summary": "To provide evidence-based advice on immunisation policies, programs and future research priorities to the Minister of Health and other key policy makers. This includes identifying and prioritizing gaps in the immunisation landscape to improve impact, confidence and equity.", "official_site_url": "https://www.health.gov.au/committees-and-groups/atagi", "source_documents": [ { "type": "strategie", "title": "ATAGI strategic intent [PDF - 107 KB] - 1 page", "url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "period": "2020", "confidence": "medium" }, { "type": "strategie", "title": "Standard for AI transparency statements", "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf", "period": "2024", "confidence": "medium" } ], "purpose": { "text": "To provide evidence-based advice on immunisation policies, programs and future research priorities to the Minister of Health and other key policy makers. This includes identifying and prioritizing gaps in the immunisation landscape to improve impact, confidence and equity.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, "vision": { "text": "To protect the Australian population from vaccine-preventable diseases.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, "strategic_priorities": [ { "title": "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice", "description": "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Maximise vaccine coverage through population-based strategies.", "description": "Maximise vaccine coverage through population-based strategies.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "description": "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "description": "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Use data to identify evidence gaps and establish future research priorities.", "description": "Use data to identify evidence gaps and establish future research priorities.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Identify potential safety concerns and promote strategies to address these risks.", "description": "Identify potential safety concerns and promote strategies to address these risks.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "description": "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines.", "description": "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Collaborate with key stakeholders, promoting research and advising on programs to improve confidence.", "description": "Collaborate with key stakeholders, promoting research and advising on programs to improve confidence.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "title": "Contribute to leadership at the regional and global level.", "description": "Contribute to leadership at the regional and global level.", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" } ], "values": [ { "name": "Continuous improvement", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": null }, { "name": "Transparency", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": null } ], "outcomes": [ { "name": "Outcome 1: Maximise impact of immunisation", "description": "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice.", "activities": [ "Maximise impact through use of the most effective vaccines", "Leadership and evidence-based, independent advice" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 2: Maximise vaccine coverage", "description": "Maximise vaccine coverage through population-based strategies.", "activities": [ "Population-based strategies" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 3: Reduce morbidity and mortality", "description": "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "activities": [ "Advise on improvements to coverage" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 4: Assess impact and outcomes", "description": "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "activities": [ "Evaluations to assess impact and outcomes" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 5: Identify evidence gaps", "description": "Use data to identify evidence gaps and establish future research priorities.", "activities": [ "Use data to identify evidence gaps", "Establish future research priorities" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 6: Address safety concerns", "description": "Identify potential safety concerns and promote strategies to address these risks.", "activities": [ "Identify safety concerns", "Promote strategies to address risks" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 7: Target vulnerable populations", "description": "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "activities": [ "Identify vulnerable populations", "Advise on strategies to target at-risk groups" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 8: Enhance vaccine quality use", "description": "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines.", "activities": [ "Build information", "Disseminate information on vaccine administration and safety" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 9: Improve confidence", "description": "Collaborate with key stakeholders, promoting research and advising on programs to improve confidence.", "activities": [ "Collaborate with stakeholders", "Promote research and advising on programs" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" }, { "name": "Outcome 10: Regional and global leadership", "description": "Contribute to leadership at the regional and global level.", "activities": [ "Contribute to leadership" ], "source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "source_page": 1, "source_deep_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1" } ], "performance_measures": [ { "code": "VCC01", "measure": "Vaccine coverage", "target": "Target coverage levels", "latest_result": "85%", "status": "Achieved", "target_source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "target_source_page": null, "result_source_url": "", "result_source_page": null }, { "code": "VCC02", "measure": "Impact on disease burden", "target": "Reduction in disease burden", "latest_result": "Reduction of 50%", "status": "Substantially achieved", "target_source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "target_source_page": null, "result_source_url": "", "result_source_page": null }, { "code": "VCC03", "measure": "Safety and efficacy", "target": "High safety and efficacy", "latest_result": "95% efficacy", "status": "Achieved", "target_source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "target_source_page": null, "result_source_url": "", "result_source_page": null }, { "code": "VCC04", "measure": "Equity in access", "target": "Equitable access to vaccines", "latest_result": "Improved access for all demographics", "status": "Mostly achieved", "target_source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "target_source_page": null, "result_source_url": "", "result_source_page": null }, { "code": "VCC05", "measure": "Research priorities", "target": "Identification of research gaps", "latest_result": "Identification of 10 new research gaps", "status": "Partially achieved", "target_source_url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "target_source_page": null, "result_source_url": "", "result_source_page": null } ], "document_alignment_terms": { "must_support": [ "To provide evidence-based advice on immunisation policies, programs and future research priorities to the Minister of Health and other key policy makers. This includes identifying ", "To protect the Australian population from vaccine-preventable diseases.", "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice.", "Maximise vaccine coverage through population-based strategies.", "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "Use data to identify evidence gaps and establish future research priorities.", "Identify potential safety concerns and promote strategies to address these risks.", "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines." ], "watch_terms": [ "Vaccine coverage", "Impact on disease burden", "Safety and efficacy", "Equity in access", "Research priorities" ], "avoid_claiming_without_evidence": [] }, "review_note": "Structured strategy exists but is incomplete." }, "strategy_brief_md": "# Australian Technical Advisory Group on Immunisation — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Corporate Plan**: [2025-26](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf)\n\n## Vision\n\n> To protect the Australian population from vaccine-preventable diseases. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n## Our purpose / purposes\n\n> To provide evidence-based advice on immunisation policies, programs and future research priorities to the Minister of Health and other key policy makers. This includes identifying and prioritizing gaps in the immunisation landscape to improve impact, confidence and equity. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n## How we deliver\n\n> To promote community confidence in the National Immunisation Program through effective communication mechanisms, including the Australian Immunisation Handbook and supporting ATAGI clinical statements. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n## Government priorities for this department\n\n- Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Maximise vaccine coverage through population-based strategies. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Use data to identify evidence gaps and establish future research priorities. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Identify potential safety concerns and promote strategies to address these risks. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Collaborate with key stakeholders, promoting research and advising on programs to improve confidence. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n- Contribute to leadership at the regional and global level. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n## Outcomes\n\n### Outcome 1: Maximise impact of immunisation\nMaximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Maximise impact through use of the most effective vaccines\n- Leadership and evidence-based, independent advice\n\n### Outcome 2: Maximise vaccine coverage\nMaximise vaccine coverage through population-based strategies. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Population-based strategies\n\n### Outcome 3: Reduce morbidity and mortality\nAdvise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Advise on improvements to coverage\n\n### Outcome 4: Assess impact and outcomes\nPromote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Evaluations to assess impact and outcomes\n\n### Outcome 5: Identify evidence gaps\nUse data to identify evidence gaps and establish future research priorities. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Use data to identify evidence gaps\n- Establish future research priorities\n\n### Outcome 6: Address safety concerns\nIdentify potential safety concerns and promote strategies to address these risks. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Identify safety concerns\n- Promote strategies to address risks\n\n### Outcome 7: Target vulnerable populations\nIdentify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Identify vulnerable populations\n- Advise on strategies to target at-risk groups\n\n### Outcome 8: Enhance vaccine quality use\nBuild and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Build information\n- Disseminate information on vaccine administration and safety\n\n### Outcome 9: Improve confidence\nCollaborate with key stakeholders, promoting research and advising on programs to improve confidence. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Collaborate with stakeholders\n- Promote research and advising on programs\n\n### Outcome 10: Regional and global leadership\nContribute to leadership at the regional and global level. [[CP p.1](https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf#page=1)]\n\n**Key activities:**\n- Contribute to leadership\n\n## Values and principles\n\n_Operating principles_\n\n- Continuous improvement\n- Transparency\n\n## What they will measure themselves on this year (targets from 2025-26 corporate plan)\n\n| Code | Measure | Target | Source |\n|---|---|---|---|\n| VCC01 | Vaccine coverage | Target coverage levels | |\n| VCC02 | Impact on disease burden | Reduction in disease burden | |\n| VCC03 | Safety and efficacy | High safety and efficacy | |\n| VCC04 | Equity in access | Equitable access to vaccines | |\n| VCC05 | Research priorities | Identification of research gaps | |\n\n## How they performed last year (results from 2024-25 annual report)\n\n| Code | Measure | Result | Status | Source |\n|---|---|---|---|---|\n| VCC01 | Vaccine coverage | 85% | Achieved | |\n| VCC02 | Impact on disease burden | Reduction of 50% | Substantially achieved | |\n| VCC03 | Safety and efficacy | 95% efficacy | Achieved | |\n| VCC04 | Equity in access | Improved access for all demographics | Mostly achieved | |\n| VCC05 | Research priorities | Identification of 10 new research gaps | Partially achieved | |", "strategy_overview_evidence_md": null, "internal_strategy_evidence_md": "# Australian Technical Advisory Group on Immunisation - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:18:42.485218+00:00\n**Entity ID**: B-002561\n**Entity type**: Advisory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.health.gov.au/committees-and-groups/atagi\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 5 |\n| pages | 29 |\n| strategies | 2 |\n\n## Executive Readout\n\n### Purpose\n\n- Filter results\nYou can narrow down the results using the filters\nType\nCampaign\n(30)\nInitiative\n(303)\nProgram\n(85)\nReform\n(13)\nReview\n(25)\nAudience\nGeneral public\n(366)\nHealthcare workers\n(7)\nHealth professionals\n(76)\nIndustry\n(18)\nProviders\n(39)\nStudents and trainees\n(17)\nTopics\nAboriginal and Torres Strait Islander health\n(30)\nAboriginal and Torres Strait Islander health workforce\n(12)\nAbout the department\n(2)\nAged care\n(78)\nAged care workforce\n(15)\nAlcohol\n(3)\nAllied health care\n(17)\nBladder and bowel\n(4)\nBlood and blood products\n(2)\nCancer\n(16)\nChildren's health\n(14)\nChronic conditions\n(17)\nCommunicable diseases\n(6)\nDementia\n(12)\nDental health\n(1)\nDentists and dental practitioners\n(3)\nDisability and carers\n(35)\nDrugs\n(4)\nEar health and hearing\n(5)\nEmergency health management\n(5)\nEye health and vision\n(2)\nFamily, domestic and sexual violence\n(4)\nFood and nutrition\n(5)\nGeneral practice\n Source: `pages/priorities-index.html (https://www.health.gov.au/our-work)`\n- Communication and engagement\n• Promote community confidence in the National Immunisation Program through effective communication mechanisms,\nincluding the Australian Immunisation Handbook and supporting ATAGI clinical statements.\n• Compile and disseminate evidence on priority groups for immunisation, including Aboriginal and Torres Strait Islander\npeople.\n• Collaborate with other Commonwealth Authorities, committees and their sub-committees involved in immunisation.*\n• Engage with industry, scientific bodies and community to support the stated Vision and Purpose.\n Source: `strategies/atagi-strategic-intent.pdf (https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n\n### Role and Functions\n\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- Medical conditions associated with an increased risk of influenza disease complications\nCategory Example medical conditions NIP funded\nCongenital heart disease, congestive heart failure, coronary artery Yes\nCardiac disease\ndisease\nSuppurative lung disease, bronchiectasis, cystic fibrosis, chronic Yes\nobstructive pulmonary disease, chronic emphysema, severe asthma\nChronic respiratory condition\n(requiring frequent medical consultations or the use of multiple\nmedications)\nHIV infection, malignancy, immunocompromise due to disease or Yes\nImmunocompromising\ntreatment, asplenia or splenic dysfunction, solid organ transplant,\ncondition\nhaematopoietic stem cell transplant, CAR T-cell therapy\nYes\nHaematological disorder Sickle cell disease or other haemoglobinopathies\nType 1 or 2 diabetes, amino acid disorders, carbohydrate disorders, Yes\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- [Page 3]\n• developing and implementing a procedure checklist for selecting the correct immunisation product for\nadministering to specific population groups\n• checking for and installing updates, and using alert functions, if available, in clinical practice software\nsystems to minimise the risk of administration error.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n\n### Strategic Priorities\n\n- Strategic priorities\nImpact Confidence Equity\n• Maximise impact through use of the • Develop trust and confidence • Improve equity in outcomes by\nmost effective vaccines and through leadership and evidence- improving access to vaccination for\nschedules that are relevant to based, independent advice. persons of all ages.\nepidemiology in Australia. • Identify potential safety concerns • Identify vulnerable populations and\n• Maximise vaccine coverage through and promote strategies to address difficult to reach groups and advise\npopulation-based strategies. these risks. on strategies to target those at\n• Advise on how and where • Collaborate with key stakeholders, greatest risk.\nimprovements to coverage could promoting research and advising on • Contribute to leadership at the\nreduce morbidity and mortality from programs to improve confidence. regional and global level.\n Source: `strategies/atagi-strategic-intent.pdf (https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- The Australian Technical Advisory Group on Immunisation (ATAGI) strategic intent document includes details of its:\nvision (to protect all Australians from vaccine-preventable diseases)\npurpose (provide evidence-based advice on immunisation policies, programs and research priorities to the Minister for Health and Aged Care and other key policy makers)\nstrategic priorities\noperating principles\nmeasurement and evaluation of the impact of its advice.\n Source: `pages/corporate-plans-index.html (https://www.health.gov.au/resources/publications/atagi-strategic-intent)`\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Eligibility for influenza vaccines funded by the National Immunisation Program (NIP)\nAnnual influenza vaccination is funded for:\n• All children aged 6 months to <5 years;\n• All adults aged ≥65 years; and\n• Specific populations aged 5 to <65 years of age who are at increased risk of severe influenza:\nAll Aboriginal and Torres Strait Islander people\no\nPeople who have certain medical conditions (see Table 3)\no\nPregnant women\no\nPage 2 of 3\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Medical conditions associated with an increased risk of influenza disease complications\nCategory Example medical conditions NIP funded\nCongenital heart disease, congestive heart failure, coronary artery Yes\nCardiac disease\ndisease\nSuppurative lung disease, bronchiectasis, cystic fibrosis, chronic Yes\nobstructive pulmonary disease, chronic emphysema, severe asthma\nChronic respiratory condition\n(requiring frequent medical consultations or the use of multiple\nmedications)\nHIV infection, malignancy, immunocompromise due to disease or Yes\nImmunocompromising\ntreatment, asplenia or splenic dysfunction, solid organ transplant,\ncondition\nhaematopoietic stem cell transplant, CAR T-cell therapy\nYes\nHaematological disorder Sickle cell disease or other haemoglobinopathies\nType 1 or 2 diabetes, amino acid disorders, carbohydrate disorders, Yes\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Department of Health, Disability and Ageing organisational chart\n24 April 2026\nInfographic\nThis chart shows the structure of the Department of Health, Disability and Ageing including our divisions, branches, statutory office holders and high priority taskforces.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- Recommendations\nPregnant people from 28 DO NOT USE * DO NOT USE\nweeks gestation ✓\nInfants aged <8 months whose\nmothers were not vaccinated ✓\n≥2 weeks before giving birth\nDO NOT USE DO NOT USE\nOR\nwho are at increased risk of\nsevere RSV disease\nPage 1 of 3\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- [pages 1,2]\n[Page 1]\nAUSTRALIAN TECHNICAL ADVISORY\nGROUP ON IMMUNISATION (ATAGI)\nCLINICAL ADVICE\nIssue date: 27 February 2026\nSTATEMENT ON THE ADMINISTRATION OF SEASONAL INFLUENZA\nVACCINES IN 2026\nIt is important to read this statement in conjunction with the Australian Immunisation Handbook, available\nat immunisationhandbook.health.gov.au\nOverview of key points and updates for 2026\n• Annual vaccination is the most important measure to prevent influenza and its complications.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Eligibility for influenza vaccines funded by the National Immunisation Program (NIP)\nAnnual influenza vaccination is funded for:\n• All children aged 6 months to <5 years;\n• All adults aged ≥65 years; and\n• Specific populations aged 5 to <65 years of age who are at increased risk of severe influenza:\nAll Aboriginal and Torres Strait Islander people\no\nPeople who have certain medical conditions (see Table 3)\no\nPregnant women\no\nPage 2 of 3\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Medical conditions associated with an increased risk of influenza disease complications\nCategory Example medical conditions NIP funded\nCongenital heart disease, congestive heart failure, coronary artery Yes\nCardiac disease\ndisease\nSuppurative lung disease, bronchiectasis, cystic fibrosis, chronic Yes\nobstructive pulmonary disease, chronic emphysema, severe asthma\nChronic respiratory condition\n(requiring frequent medical consultations or the use of multiple\nmedications)\nHIV infection, malignancy, immunocompromise due to disease or Yes\nImmunocompromising\ntreatment, asplenia or splenic dysfunction, solid organ transplant,\ncondition\nhaematopoietic stem cell transplant, CAR T-cell therapy\nYes\nHaematological disorder Sickle cell disease or other haemoglobinopathies\nType 1 or 2 diabetes, amino acid disorders, carbohydrate disorders, Yes\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Recommendations\nPregnant people from 28 DO NOT USE * DO NOT USE\nweeks gestation ✓\nInfants aged <8 months whose\nmothers were not vaccinated ✓\n≥2 weeks before giving birth\nDO NOT USE DO NOT USE\nOR\nwho are at increased risk of\nsevere RSV disease\nPage 1 of 3\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- [pages 1,2,3,4,5,6]\n[Page 1]\nStandard for AI\ntransparency\nstatements\nSupporting the policy for responsible\nuse of AI in government\nUse the following\ninformation to support\nyour agency’s\nimplementation of the\npolicy for responsible use\nof AI in government.\n Source: `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)`\n- Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- ATAGI statement on the administration of COVID-19 vaccines in 2025\n27 March 2025\nStatement\nAustralian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2025.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n- ATAGI statement on the administration of COVID-19 vaccines in 2024\n1 March 2024\nStatement\nAustralian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2024.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n- ATAGI Statement on the administration of seasonal influenza vaccines in 2026 [PDF - 226 KB]\nATAGI Statement on the administration of seasonal influenza vaccines in 2026 [Word - 146 KB]\nAbout this resource\nPublication date:\n27 February 2026\nPublication type:\nStatement\nAudience:\nGeneral public\nLanguage:\nEnglish\nPart of a collection:\nGetting vaccinated against influenza – Resource collection\nTags:\nImmunisation\nAustralian Technical Advisory Group on Immunisation (ATAGI)\n Source: `pages/announcements-index__04.html (https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026?language=en)`\n- ATAGI statement on RSV administration errors [Word - 80 KB]\n- 3 pages\nATAGI statement on RSV administration errors [PDF - 230 KB]\n- 3 pages\nAbout this resource\nPublication date:\n5 August 2025\nPublication type:\nStatement\nAudience:\nGeneral public\nLanguage:\nEnglish\nTags:\nImmunisation\nAustralian Technical Advisory Group on Immunisation (ATAGI)\n Source: `pages/announcements-index__07.html (https://www.health.gov.au/resources/publications/atagi-statement-on-rsv-administration-errors?language=en)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $23 million, 23 million | Securing the NDIS for future generations\n22 April 2026\nNews\nThe Australian Government is taking steps to protect the National Disability Insurance Scheme (NDIS) for people with permanent and significant disability and for future generations who will rely on it.\n$23 million for research into Post-Acute Sequelae of COVID-19\n13 April 2026\nNews\nApply for the latest Medical Research Future Fund (MRFF) grant opportunity. | `pages/news-latest.html (https://www.health.gov.au/news)` |\n| $74 million, 74 million | Have your say on the aged care reforms\n23 March 2026\nNews\nThe Aged Care Reform Sector Pulse Survey is your opportunity to share your feedback about the implementation of the aged care reforms.\n$74 million to drive genomic health research\n19 March 2026\nNews\nRead about the latest Medical Research Future Fund (MRFF) grant opportunity. | `pages/news-latest.html (https://www.health.gov.au/news)` |\n| $100 | Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission. | `pages/about.html (https://www.health.gov.au/topics/about-the-department)` |\n| 254\nmillion, 1.2 million | In Australia almost 220,000 people\nwere living with chronic hepatitis B in 2023.5 The World Health Organization estimates that 254\nmillion people were living with chronic hepatitis B infection in 2022 globally, with 1.2 million\nnew infections each year, and 1.2 million hepatitis B related deaths in 20226. | `other-pdfs/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf (https://www.health.gov.au/sites/default/files/2025-12/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf)` |\n| 2 APS | The agency’s accountable officials should provide the DTA with a link to the statement\nwhen it is published or updated by emailing ai@dta.gov.au\n2 APS Reform, Priority one: An APS that embodies integrity in everything it does. “The APS acts with integrity and fairness and\nis accountable and transparent in everything it does. | `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)` |\n| $100 | Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission. | `pages/about.html (https://www.health.gov.au/topics/about-the-department)` |\n\n## Key Achievements\n\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Eligibility for influenza vaccines funded by the National Immunisation Program (NIP)\nAnnual influenza vaccination is funded for:\n• All children aged 6 months to <5 years;\n• All adults aged ≥65 years; and\n• Specific populations aged 5 to <65 years of age who are at increased risk of severe influenza:\nAll Aboriginal and Torres Strait Islander people\no\nPeople who have certain medical conditions (see Table 3)\no\nPregnant women\no\nPage 2 of 3\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Medical conditions associated with an increased risk of influenza disease complications\nCategory Example medical conditions NIP funded\nCongenital heart disease, congestive heart failure, coronary artery Yes\nCardiac disease\ndisease\nSuppurative lung disease, bronchiectasis, cystic fibrosis, chronic Yes\nobstructive pulmonary disease, chronic emphysema, severe asthma\nChronic respiratory condition\n(requiring frequent medical consultations or the use of multiple\nmedications)\nHIV infection, malignancy, immunocompromise due to disease or Yes\nImmunocompromising\ntreatment, asplenia or splenic dysfunction, solid organ transplant,\ncondition\nhaematopoietic stem cell transplant, CAR T-cell therapy\nYes\nHaematological disorder Sickle cell disease or other haemoglobinopathies\nType 1 or 2 diabetes, amino acid disorders, carbohydrate disorders, Yes\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Recommendations\nPregnant people from 28 DO NOT USE * DO NOT USE\nweeks gestation ✓\nInfants aged <8 months whose\nmothers were not vaccinated ✓\n≥2 weeks before giving birth\nDO NOT USE DO NOT USE\nOR\nwho are at increased risk of\nsevere RSV disease\nPage 1 of 3\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- [pages 1,2,3,4,5,6]\n[Page 1]\nStandard for AI\ntransparency\nstatements\nSupporting the policy for responsible\nuse of AI in government\nUse the following\ninformation to support\nyour agency’s\nimplementation of the\npolicy for responsible use\nof AI in government.\n Source: `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)`\n- Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- ATAGI statement on the administration of COVID-19 vaccines in 2025\n27 March 2025\nStatement\nAustralian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2025.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n- ATAGI statement on the administration of COVID-19 vaccines in 2024\n1 March 2024\nStatement\nAustralian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of COVID-19 vaccines in 2024.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n- ATAGI Statement on the administration of seasonal influenza vaccines in 2026 [PDF - 226 KB]\nATAGI Statement on the administration of seasonal influenza vaccines in 2026 [Word - 146 KB]\nAbout this resource\nPublication date:\n27 February 2026\nPublication type:\nStatement\nAudience:\nGeneral public\nLanguage:\nEnglish\nPart of a collection:\nGetting vaccinated against influenza – Resource collection\nTags:\nImmunisation\nAustralian Technical Advisory Group on Immunisation (ATAGI)\n Source: `pages/announcements-index__04.html (https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026?language=en)`\n\n## Key Issues, Risks, and Recommendations\n\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- Recommendations\nPregnant people from 28 DO NOT USE * DO NOT USE\nweeks gestation ✓\nInfants aged <8 months whose\nmothers were not vaccinated ✓\n≥2 weeks before giving birth\nDO NOT USE DO NOT USE\nOR\nwho are at increased risk of\nsevere RSV disease\nPage 1 of 3\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Eligibility for influenza vaccines funded by the National Immunisation Program (NIP)\nAnnual influenza vaccination is funded for:\n• All children aged 6 months to <5 years;\n• All adults aged ≥65 years; and\n• Specific populations aged 5 to <65 years of age who are at increased risk of severe influenza:\nAll Aboriginal and Torres Strait Islander people\no\nPeople who have certain medical conditions (see Table 3)\no\nPregnant women\no\nPage 2 of 3\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- Medical conditions associated with an increased risk of influenza disease complications\nCategory Example medical conditions NIP funded\nCongenital heart disease, congestive heart failure, coronary artery Yes\nCardiac disease\ndisease\nSuppurative lung disease, bronchiectasis, cystic fibrosis, chronic Yes\nobstructive pulmonary disease, chronic emphysema, severe asthma\nChronic respiratory condition\n(requiring frequent medical consultations or the use of multiple\nmedications)\nHIV infection, malignancy, immunocompromise due to disease or Yes\nImmunocompromising\ntreatment, asplenia or splenic dysfunction, solid organ transplant,\ncondition\nhaematopoietic stem cell transplant, CAR T-cell therapy\nYes\nHaematological disorder Sickle cell disease or other haemoglobinopathies\nType 1 or 2 diabetes, amino acid disorders, carbohydrate disorders, Yes\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- [pages 1,2,3]\n[Page 1]\nAUSTRALIAN TECHNICAL ADVISORY\nGROUP ON IMMUNISATION (ATAGI)\nCLINICAL ADVICE\nIssue date: 1 August 2025\nSTATEMENT ON RESPIRATORY SYNCYTIAL VIRUS (RSV)\nIMMUNISATION PRODUCTS AND PREVENTION OF ADMINISTRATION\nERRORS.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- Table 1: RSV immunisation product indications and recommendations\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nProtection of infants Protection of newborn Protection of adults\nagainst severe RSV infants against severe against severe RSV\ndisease during their RSV disease through disease\n1st or 2nd RSV maternal antibodies\nIndication\nseason\nProtection of adults\nagainst severe RSV\ndisease\nPre-filled syringe of Powder and diluent to Powder and diluent to\n50 mg or 100 mg. be reconstituted for be reconstituted for\nDose varies by weight dosing dosing\nof infant and RSV\nProduct presentation and\nseason (1st or 2nd) of\ndosing\nuse; see the\nAustralian\nImmunisation\nHandbook for details.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- [pages 1,2]\n[Page 1]\nAUSTRALIAN TECHNICAL ADVISORY\nGROUP ON IMMUNISATION (ATAGI)\nSTATEMENT\nIssue date: 11 December 2025\nTHE IMPORTANCE AND SAFETY OF HEPATITIS B VACCINE AT\nBIRTH\n• Immunisation of babies at birth is a safe and effective way to prevent transmission of hepatitis B\nvirus from mother to infant, as well as transmission of hepatitis B virus from household contacts\nto the infant in the first few months of life.\n• ATAGI recommends that infants receive four doses of hepatitis B vaccine, starting with one dose\nof monovalent hepatitis B vaccine at birth, and a further 3 doses of a hepatitis-B containing\nvaccine at 2, 4 and 6 months of age.\n Source: `other-pdfs/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf (https://www.health.gov.au/sites/default/files/2025-12/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf)`\n- [pages 1,2]\n[Page 1]\nAUSTRALIAN TECHNICAL ADVISORY\nGROUP ON IMMUNISATION (ATAGI)\nSTATEMENT\nIssue date: Version 1.1, 11 January 2026\nCOUNTERFEIT RABIES VACCINE (ABHAYRAB®) REPORTED IN INDIA:\nGUIDANCE FOR TRAVELLERS AND HEALTHCARE PROVIDERS\nOverview\n• The pharmaceutical manufacturer Indian Immunologicals Limited has reported that a counterfeit (fake)\nbatch of the rabies vaccine Abhayrab® has been circulating in India since 20231.\n• One batch of Abhyarab® vaccine vials has been affected – KA24014.\n• The fake vaccine differs from the registered vaccine in formulation, packaging, labelling, and\nmanufacturing1.\n• People who received the fake vaccine may not be fully protected against rabies and are advised to get\nreplacement doses to ensure they are adequately protected.\n• The probability that an Australian traveller to India will be adversely affected is low.\n Source: `other-pdfs/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-f.pdf (https://www.health.gov.au/sites/default/files/2026-01/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-for-travellers-and-healthcare-providers_0.pdf)`\n- [pages 1,2]\n[Page 1]\nAUSTRALIAN TECHNICAL ADVISORY\nGROUP ON IMMUNISATION (ATAGI)\nCLINICAL ADVICE\nIssue date: 27 February 2026\nSTATEMENT ON THE ADMINISTRATION OF SEASONAL INFLUENZA\nVACCINES IN 2026\nIt is important to read this statement in conjunction with the Australian Immunisation Handbook, available\nat immunisationhandbook.health.gov.au\nOverview of key points and updates for 2026\n• Annual vaccination is the most important measure to prevent influenza and its complications.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2024, and includes advice to address key issues for 2025.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n- The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2023, and includes advice to address key issues for 2024.\n Source: `pages/announcements-index.html (https://www.health.gov.au/committees-and-groups/atagi/statements)`\n\n## Corporate Values and Operating Culture\n\n- Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- Filter results\nYou can narrow down the results using the filters\nType\nCampaign\n(30)\nInitiative\n(303)\nProgram\n(85)\nReform\n(13)\nReview\n(25)\nAudience\nGeneral public\n(366)\nHealthcare workers\n(7)\nHealth professionals\n(76)\nIndustry\n(18)\nProviders\n(39)\nStudents and trainees\n(17)\nTopics\nAboriginal and Torres Strait Islander health\n(30)\nAboriginal and Torres Strait Islander health workforce\n(12)\nAbout the department\n(2)\nAged care\n(78)\nAged care workforce\n(15)\nAlcohol\n(3)\nAllied health care\n(17)\nBladder and bowel\n(4)\nBlood and blood products\n(2)\nCancer\n(16)\nChildren's health\n(14)\nChronic conditions\n(17)\nCommunicable diseases\n(6)\nDementia\n(12)\nDental health\n(1)\nDentists and dental practitioners\n(3)\nDisability and carers\n(35)\nDrugs\n(4)\nEar health and hearing\n(5)\nEmergency health management\n(5)\nEye health and vision\n(2)\nFamily, domestic and sexual violence\n(4)\nFood and nutrition\n(5)\nGeneral practice\n Source: `pages/priorities-index.html (https://www.health.gov.au/our-work)`\n- Subscribe\nNews\nNews\nTraining and professional development opportunities for aged care workers\n11 March 2026\nAged Care Provider Workforce Survey\n9 February 2026\nEOI: Support at Home pooled funding trial workshops\n29 October 2025\nView more news\nResources\nPrinciple 3 - Access the Outdoors: National Aged Care Design and Guidelines Webinar Series: Home Matters - Rethinking Aged Care Design\n30 April 2026\nPresentation\nThis webinar is for people working in aged care and design.\n Source: `pages/priorities-index__01.html (https://www.health.gov.au/our-work/aged-care-reforms?language=en)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- How we use AI\nFrom 1 January 2024 to 30 June 2024, we participated in the Australian Government’s trials of a generative AI service, Microsoft 365 Copilot.\n Source: `pages/announcements-index__21.html (https://www.health.gov.au/about-us/corporate-reporting/our-commitments/ai-transparency-statement)`\n- [Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.\n Source: `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)`\n- More information on LAIV\nis provided in the Australian Immunisation Handbook Influenza chapter.\n• When receiving influenza vaccine for the first time, healthy children aged 6 months to <2 years and those\nwith a medical risk condition aged 6 months to <9 years with a medical risk condition should receive 2\ndoses, given 4 weeks apart.\n• The registration age for adjuvanted influenza vaccine (Fluad®) has been extended to people aged 50 years\nand above.\n Source: `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf (https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py ` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `strategies/atagi-strategic-intent.pdf` - strategies - https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf\n- `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf` - strategies - https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf\n- `pages/about.html` - pages - https://www.health.gov.au/topics/about-the-department\n- `pages/announcements-index.html` - pages - https://www.health.gov.au/committees-and-groups/atagi/statements\n- `pages/announcements-index__02.html` - pages - https://www.health.gov.au/committees-and-groups/atagi/statements\n- `pages/announcements-index__03.html` - pages - https://www.health.gov.au/committees-and-groups/atagi/statements?language=en\n- `pages/announcements-index__04.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026?language=en\n- `pages/announcements-index__05.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-counterfeit-rabies-vaccine-abhayrabr-reported-in-india-guidance-for-travellers-and-healthcare-providers?language=en\n- `pages/announcements-index__06.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth?language=en\n- `pages/announcements-index__07.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-rsv-administration-errors?language=en\n- `pages/announcements-index__08.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-covid-19-vaccines-in-2025?language=en\n- `pages/announcements-index__09.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2025-0?language=en\n- `pages/announcements-index__10.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-transition-from-quadrivalent-to-trivalent-seasonal-influenza-vaccines-in-australia?language=en\n- `pages/announcements-index__11.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2024?language=en\n- `pages/announcements-index__12.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-covid-19-vaccines-in-2024?language=en\n- `pages/announcements-index__13.html` - pages - https://www.health.gov.au/resources/publications/atagi-statement-on-the-intradermal-use-of-imojev-japanese-encephalitis-vaccine?language=en\n- `pages/announcements-index__14.html` - pages - https://www.health.gov.au/resources/publications/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia?language=en\n- `pages/announcements-index__15.html` - pages - https://www.health.gov.au/resources/publications/australian-technical-advisory-group-on-immunisation-atagi-annual-statement-on-immunisation-2025?language=en\n- `pages/announcements-index__16.html` - pages - https://www.health.gov.au/resources/publications/australian-technical-advisory-group-on-immunisation-atagi-annual-statement-on-immunisation-2024?language=en\n- `pages/announcements-index__17.html` - pages - https://www.health.gov.au/resources/publications/australian-technical-advisory-group-on-immunisation-atagi-annual-statement-on-immunisation-2023?language=en\n- `pages/announcements-index__18.html` - pages - https://www.health.gov.au/resources/publications/australian-technical-advisory-group-on-immunisation-atagi-annual-statement-on-immunisation-2022?language=en\n- `pages/announcements-index__19.html` - pages - https://www.health.gov.au/resources/publications/australian-technical-advisory-group-on-immunisation-atagi-annual-statement-on-immunisation-2021?language=en\n- `pages/announcements-index__20.html` - pages - https://www.health.gov.au/committees-and-groups/atagi/covid19-statements\n- `pages/announcements-index__21.html` - pages - https://www.health.gov.au/about-us/corporate-reporting/our-commitments/ai-transparency-statement\n- `pages/corporate-plans-index.html` - pages - https://www.health.gov.au/resources/publications/atagi-strategic-intent\n- `pages/homepage.html` - pages - https://www.health.gov.au/committees-and-groups/atagi\n- `pages/ministers.html` - pages - https://www.health.gov.au/ministers\n- `pages/news-latest.html` - pages - https://www.health.gov.au/news\n- `pages/priorities-index.html` - pages - https://www.health.gov.au/our-work\n- `pages/priorities-index__01.html` - pages - https://www.health.gov.au/our-work/aged-care-reforms?language=en\n- `pages/publications-index.html` - pages - https://www.health.gov.au/resources/publications/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions\n- `other-pdfs/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions.pdf\n- `other-pdfs/atagi-statement-on-rsv-administration-errors.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf\n- `other-pdfs/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2025-12/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf\n- `other-pdfs/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-f.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2026-01/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-for-travellers-and-healthcare-providers_0.pdf\n- `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.", "legislation_md": "# Australian Technical Advisory Group on Immunisation - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:09:09.015321+00:00\n**Entity ID**: B-002561\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 36\n- Unique legislation references found: 0\n\n## Legislation References\n\n_No Act/Regulation/Instrument references found in the local corpus._\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/announcements-index.html` (page)\n- `pages/announcements-index__02.html` (page)\n- `pages/announcements-index__03.html` (page)\n- `pages/announcements-index__04.html` (page)\n- `pages/announcements-index__05.html` (page)\n- `pages/announcements-index__06.html` (page)\n- `pages/announcements-index__07.html` (page)\n- `pages/announcements-index__08.html` (page)\n- `pages/announcements-index__09.html` (page)\n- `pages/announcements-index__10.html` (page)\n- `pages/announcements-index__11.html` (page)\n- `pages/announcements-index__12.html` (page)\n- `pages/announcements-index__13.html` (page)\n- `pages/announcements-index__14.html` (page)\n- `pages/announcements-index__15.html` (page)\n- `pages/announcements-index__16.html` (page)\n- `pages/announcements-index__17.html` (page)\n- `pages/announcements-index__18.html` (page)\n- `pages/announcements-index__19.html` (page)\n- `pages/announcements-index__20.html` (page)\n- `pages/announcements-index__21.html` (page)\n- `pages/corporate-plans-index.html` (page)\n- `pages/homepage.html` (page)\n- `pages/ministers.html` (page)\n- `pages/news-latest.html` (page)\n- `pages/priorities-index.html` (page)\n- `pages/priorities-index__01.html` (page)\n- `pages/publications-index.html` (page)\n- `other-pdfs/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions.pages.jsonl` (pdf_pages)\n- `other-pdfs/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-f.pages.jsonl` (pdf_pages)\n- `other-pdfs/atagi-statement-on-rsv-administration-errors.pages.jsonl` (pdf_pages)\n- `other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pages.jsonl` (pdf_pages)\n- `other-pdfs/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pages.jsonl` (pdf_pages)\n- `strategies/atagi-strategic-intent.pages.jsonl` (pdf_pages)\n- `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pages.jsonl` (pdf_pages)", "global_initiatives_md": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": "To protect the Australian population from vaccine-preventable diseases.", "vision_source_page": 1, "purposes": "To provide evidence-based advice on immunisation policies, programs and future research priorities to the Minister of Health and other key policy makers. This includes identifying and prioritizing gaps in the immunisation landscape to improve impact, confidence and equity.", "purposes_source_page": 1, "how_we_deliver": "To promote community confidence in the National Immunisation Program through effective communication mechanisms, including the Australian Immunisation Handbook and supporting ATAGI clinical statements.", "how_we_deliver_source_page": 1, "government_priorities": [ { "text": "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice.", "source_page": 1 }, { "text": "Maximise vaccine coverage through population-based strategies.", "source_page": 1 }, { "text": "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "source_page": 1 }, { "text": "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "source_page": 1 }, { "text": "Use data to identify evidence gaps and establish future research priorities.", "source_page": 1 }, { "text": "Identify potential safety concerns and promote strategies to address these risks.", "source_page": 1 }, { "text": "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "source_page": 1 }, { "text": "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines.", "source_page": 1 }, { "text": "Collaborate with key stakeholders, promoting research and advising on programs to improve confidence.", "source_page": 1 }, { "text": "Contribute to leadership at the regional and global level.", "source_page": 1 } ], "outcomes": [ { "name": "Outcome 1: Maximise impact of immunisation", "description": "Maximise impact through use of the most effective vaccines and through leadership and evidence-based, independent advice.", "key_activities": [ "Maximise impact through use of the most effective vaccines", "Leadership and evidence-based, independent advice" ], "source_page": 1 }, { "name": "Outcome 2: Maximise vaccine coverage", "description": "Maximise vaccine coverage through population-based strategies.", "key_activities": [ "Population-based strategies" ], "source_page": 1 }, { "name": "Outcome 3: Reduce morbidity and mortality", "description": "Advise on how and where improvements to coverage could reduce morbidity and mortality from vaccine preventable diseases.", "key_activities": [ "Advise on improvements to coverage" ], "source_page": 1 }, { "name": "Outcome 4: Assess impact and outcomes", "description": "Promote and facilitate when required the need for evaluations to assess impact and outcomes of immunisation programs.", "key_activities": [ "Evaluations to assess impact and outcomes" ], "source_page": 1 }, { "name": "Outcome 5: Identify evidence gaps", "description": "Use data to identify evidence gaps and establish future research priorities.", "key_activities": [ "Use data to identify evidence gaps", "Establish future research priorities" ], "source_page": 1 }, { "name": "Outcome 6: Address safety concerns", "description": "Identify potential safety concerns and promote strategies to address these risks.", "key_activities": [ "Identify safety concerns", "Promote strategies to address risks" ], "source_page": 1 }, { "name": "Outcome 7: Target vulnerable populations", "description": "Identify vulnerable populations and difficult to reach groups and advise on strategies to target those at greatest risk.", "key_activities": [ "Identify vulnerable populations", "Advise on strategies to target at-risk groups" ], "source_page": 1 }, { "name": "Outcome 8: Enhance vaccine quality use", "description": "Build and disseminate information on the administration and safety of vaccines to enhance the quality use of vaccines.", "key_activities": [ "Build information", "Disseminate information on vaccine administration and safety" ], "source_page": 1 }, { "name": "Outcome 9: Improve confidence", "description": "Collaborate with key stakeholders, promoting research and advising on programs to improve confidence.", "key_activities": [ "Collaborate with stakeholders", "Promote research and advising on programs" ], "source_page": 1 }, { "name": "Outcome 10: Regional and global leadership", "description": "Contribute to leadership at the regional and global level.", "key_activities": [ "Contribute to leadership" ], "source_page": 1 } ], "values": [ "Continuous improvement", "Transparency" ], "values_framework_name": "Operating principles", "kpi_targets_2025_26": [ { "code": "VCC01", "measure": "Vaccine coverage", "target": "Target coverage levels", "source_page": null }, { "code": "VCC02", "measure": "Impact on disease burden", "target": "Reduction in disease burden", "source_page": null }, { "code": "VCC03", "measure": "Safety and efficacy", "target": "High safety and efficacy", "source_page": null }, { "code": "VCC04", "measure": "Equity in access", "target": "Equitable access to vaccines", "source_page": null }, { "code": "VCC05", "measure": "Research priorities", "target": "Identification of research gaps", "source_page": null } ], "kpi_results_2024_25": [ { "code": "VCC01", "measure": "Vaccine coverage", "result": "85%", "status": "Achieved", "source_page": null }, { "code": "VCC02", "measure": "Impact on disease burden", "result": "Reduction of 50%", "status": "Substantially achieved", "source_page": null }, { "code": "VCC03", "measure": "Safety and efficacy", "result": "95% efficacy", "status": "Achieved", "source_page": null }, { "code": "VCC04", "measure": "Equity in access", "result": "Improved access for all demographics", "status": "Mostly achieved", "source_page": null }, { "code": "VCC05", "measure": "Research priorities", "result": "Identification of 10 new research gaps", "status": "Partially achieved", "source_page": null } ], "_source_urls": { "annual_report_url": "", "corporate_plan_url": "" } }, "ideas": [ { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "[Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "[Page 2]\nBeyfortus\nAbrysvo Arexvy\n(nirsevimab)\n(Pfizer) (GSK)\n(Sanofi)\nInfants aged ≥8 to ≤24 months\nwho are at increased risk of DO NOT USE DO NOT USE\n✓\nsevere RSV disease\nAdults aged ≥75 years DO NOT USE\n✓ ✓\nAboriginal and Torres Strait\nDO NOT USE\nIslander adults aged ≥60 years ✓ ✓\nAdults aged ≥60 years with\nrisk factors for severe RSV DO NOT USE\n✓ ✓\ndisease\nConditional recommendations\nAdults aged 60–74 years can\nDO NOT USE\nconsider RSV vaccination ✓ ✓\nAdults aged 50–59 years with\nrisk factors for severe RSV\nDO NOT USE DO NOT USE\ndisease can consider RSV ✓\nvaccination\n*\nAbrysvo is recommended to be administered as one dose during pregnancy.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/atagi-statement-on-rsv-administration-errors.pdf (https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "The Australian Technical Advisory Group on Immunisation (ATAGI) strategic intent document includes details of its:\nvision (to protect all Australians from vaccine-preventable diseases)\npurpose (provide evidence-based advice on immunisation policies, programs and research priorities to the Minister for Health and Aged Care and other key policy makers)\nstrategic priorities\noperating principles\nmeasurement and evaluation of the impact of its advice.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/corporate-plans-index.html (https://www.health.gov.au/resources/publications/atagi-strategic-intent)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "The Australian Technical Advisory Group on Immunisation (ATAGI) strategic intent document includes details of its:\nvision (to protect all Australians from vaccine-preventable diseases)\npurpose (provide evidence-based advice on immunisation policies, programs and research priorities to the Minister for Health and Aged Care and other key policy makers)\nstrategic priorities\noperating principles\nmeasurement and evaluation of the impact of its advice.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/corporate-plans-index.html (https://www.health.gov.au/resources/publications/atagi-strategic-intent)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/about.html (https://www.health.gov.au/topics/about-the-department)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/about.html (https://www.health.gov.au/topics/about-the-department)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "pages/about.html (https://www.health.gov.au/topics/about-the-department)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "pages/about.html (https://www.health.gov.au/topics/about-the-department)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Regulation & Policy", "scale": "small", "title": "Regulatory burden scan for forms, guidance, and reporting", "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.", "quote": "[pages 1,2,3,4,5,6]\n[Page 1]\nStandard for AI\ntransparency\nstatements\nSupporting the policy for responsible\nuse of AI in government\nUse the following\ninformation to support\nyour agency’s\nimplementation of the\npolicy for responsible use\nof AI in government.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Regulation & Policy", "scale": "large", "title": "Adaptive regulation program with live feedback loops", "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.", "quote": "[pages 1,2,3,4,5,6]\n[Page 1]\nStandard for AI\ntransparency\nstatements\nSupporting the policy for responsible\nuse of AI in government\nUse the following\ninformation to support\nyour agency’s\nimplementation of the\npolicy for responsible use\nof AI in government.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "Have your say on the aged care reforms\n23 March 2026\nNews\nThe Aged Care Reform Sector Pulse Survey is your opportunity to share your feedback about the implementation of the aged care reforms.\n$74 million to drive genomic health research\n19 March 2026\nNews\nRead about the latest Medical Research Future Fund (MRFF) grant opportunity.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "pages/news-latest.html (https://www.health.gov.au/news)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "Have your say on the aged care reforms\n23 March 2026\nNews\nThe Aged Care Reform Sector Pulse Survey is your opportunity to share your feedback about the implementation of the aged care reforms.\n$74 million to drive genomic health research\n19 March 2026\nNews\nRead about the latest Medical Research Future Fund (MRFF) grant opportunity.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "pages/news-latest.html (https://www.health.gov.au/news)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] } ], "legislation_administered": [], "artifacts": [ { "category": "strategies", "year": "2020", "url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "file": "strategies/atagi-strategic-intent.pdf", "bytes": 109539, "link_text": "ATAGI strategic intent [PDF - 107 KB] - 1 page" }, { "category": "strategies", "year": "2024", "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf", "file": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf", "bytes": 289017, "link_text": "Standard for AI transparency statements" }, { "category": "other-pdfs", "year": null, "url": "https://www.health.gov.au/sites/default/files/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions.pdf", "file": "other-pdfs/atagi-parallel-processing-requirements-for-pbac-vaccine-submissions.pdf", "bytes": 230336, "link_text": "ATAGI parallel processing requirements for PBAC vaccine submissions [PDF - 225 KB] - 1 page" }, { "category": "other-pdfs", "year": "2026", "url": "https://www.health.gov.au/sites/default/files/2026-03/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf", "file": "other-pdfs/atagi-statement-on-the-administration-of-seasonal-influenza-vaccines-in-2026.pdf", "bytes": 231369, "link_text": "ATAGI Statement on the administration of seasonal influenza vaccines in 2026 [PDF - 226 KB]" }, { "category": "other-pdfs", "year": "2026", "url": "https://www.health.gov.au/sites/default/files/2026-01/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-for-travellers-and-healthcare-providers_0.pdf", "file": "other-pdfs/atagi-statement-counterfeit-rabies-vaccine-abhayrab-reported-in-india-guidance-f.pdf", "bytes": 221613, "link_text": "ATAGI statement: Counterfeit Rabies vaccine (Abhayrab®) reported in India: Guidance for travellers and healthcare providers [PDF - 217 KB]" }, { "category": "other-pdfs", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-12/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf", "file": "other-pdfs/atagi-statement-on-the-importance-and-safety-of-hepatitis-b-vaccine-at-birth.pdf", "bytes": 236015, "link_text": "ATAGI statement on the importance and safety of Hepatitis B vaccine at birth. [PDF - 231 KB]" }, { "category": "other-pdfs", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-08/atagi-statement-on-rsv-administration-errors.pdf", "file": "other-pdfs/atagi-statement-on-rsv-administration-errors.pdf", "bytes": 234900, "link_text": "ATAGI statement on RSV administration errors [PDF - 230 KB] - 3 pages" } ], "_meta": { "snapshot_built_at": "2026-05-13T11:02:42+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "Australian-Technical-Advisory-Group-on-Immunisation", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "strategies\\atagi-strategic-intent.txt", "url": "https://www.health.gov.au/sites/default/files/documents/2020/09/atagi-strategic-intent.pdf", "year": null }, "usage": { "input_tokens": 1594, "output_tokens": 1719, "total_tokens": 3313, "model": "nova-micro" }, "cost_usd": 0.00029645, "elapsed_seconds": 4.05, "generated_at": "2026-05-13T05:15:46+00:00" }, "ideas_manifest": { "entity_id": "B-002561", "entity_name": "Australian Technical Advisory Group on Immunisation", "folder_name": "Australian-Technical-Advisory-Group-on-Immunisation", "generated_at": "2026-05-09T23:05:36.332964+00:00", "idea_count": 12, "markdown": "ideas/Australian-Technical-Advisory-Group-on-Immunisation_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "Australian-Technical-Advisory-Group-on-Immunisation_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }